M22 Management of Hypoglycemia and Impaired Awareness of Hypoglycemia in Diabetes

Program: Meet-the-Professor Sessions
Clinical Session
Saturday, April 2, 2016: 3:30 PM-4:15 PM
Room 107 (BCEC)
Elizabeth Rachel Seaquist, MD, University of Minnesota, Minneapolis, MN

ERS: Investigator, Eli Lilly & Company, Consultant, locemia, Investigator, locemia, Speaker, Sanofi, Speaker, Novo Nordisk.

Hypoglycemia unawareness is a dangerous condition for patients with medication treated diabetes because it is an inability of patients to detect the early warning symptoms of hypoglycemia in order to take corrective action that can prevent severe hypoglycemia. Hypoglycemia unawareness can be reduced or alleviated by careful attention to glycemic management.


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire